The first edition of EvaluatePharma’s Orphan Drug Report is in response to requests from our client base for an in-depth, fact-based analysis of the orphan drug market. To facilitate the analysis, the EvaluatePharma service has enhanced its core product database to include new orphan drug data fields and has integrated US, EU and Japan orphan designation databases.
The report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected performance of the orphan drug market between now and 2018 - view the report infographic (PDF).
Key highlights in the Orphan Drug Report 2013 include:
- The Worldwide Orphan Drug Market to Grow to $127 billion by 2018, double that of the overall prescription drug market.
- In 2012, orphan drug sales increased 7.1% to $83 billion from the previous year. That compares with a 2.1% decline in overall prescription drug sales (excluding generics), which fell to $645 billion.
- Novartis will maintain its position as the world's No. 1 orphan drug company in 2018, with expected sales of $11.8 billion.
- Kyprolis, a drug from Onyx Pharmaceuticals for multiple myeloma, was the most promising new orphan drug in 2012, with U.S. sales expected to reach $897 million in 2017.
- The number of orphan designations in the U.S. fell 7% in 2012, marking the first decline since 2007.
- Orphan designations in Europe increased 44%, reversing a decline in 2011.
- Of the 43 new drugs approved by the FDA in 2012, 15 were orphan drugs, representing 35% of the industry's new drug output.
To download the full "Orphan Drug Report 2013" confirm your details on the short form opposite.